GLP 1: Just a wonder drug or a lifesaver for millions?
India stands tall as the world’s pharmacy — now poised to lead the GLP-1 revolution. 💉 GLP-1 receptor agonists, which mimic the hormone Glucagon-Like Peptide-1, are transforming treatment for diabetes and obesity. 🩸🧍♂️ With patents set to expire soon, India could unlock access to affordable generics, driving a healthcare breakthrough. The GLP-1 market is projected to reach $578.9M by 2030, growing at a 27.5% CAGR — a massive opportunity for India’s health and pharma sectors. 📈🚀
AIF Investor Charter 
NIVESHAAY INVESTMENT ADVISORS
508, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7859870559
research.smallcase@niveshaay.com (Smallcase)
NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED
610, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7836915478
contactaif@niveshaay.com (AIF)
Watch Video
SEBI Registration No. : INH000017338, IN/AIF3/24-25/1571, IN/AIF2/24-25/1607 | BASL Membership ID: 6276
Disclaimer:
Investment in Securities Market are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
The securities quoted are for illustration only and are not recommendatory
NIVESHAAY INVESTMENT ADVISORS © . All Rights Reserved., NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED © . All Rights Reserved.Smart ODR